Biomarkers for PTLD diagnosis and therapies
Sign Up to like & getrecommendations! Published in 2019 at "Pediatric Nephrology"
DOI: 10.1007/s00467-019-04284-w
Abstract: Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of lymphoproliferative disorders and is a serious complication of pediatric transplantation. The majority of PTLD are associated with Epstein Barr virus (EBV) and the characteristic EBV+ B cell… read more here.
Keywords: diagnosis therapies; ebv ptld; ptld diagnosis; ptld ... See more keywords
Efficacy of Donor and ‘Third Party’ (Tabelecleucel) EBV-Specific T Cells for Treatment of Central Nervous System (CNS) EBV-PTLD
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.158
Abstract: Background EBV+PTLD is a life-threatening complication after hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT). Introduction of EBV-specific T-cells (EBV+CTLs) as second line treatment after rituximab has reduced overall EBV+PTLD related mortality. Due to… read more here.
Keywords: cns ebv; ebv; ebv ptld; ebv ctls ... See more keywords
Long-Term Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in a Multicenter Expanded Access Program Study
Sign Up to like & getrecommendations! Published in 2020 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2019.12.228
Abstract: Background Patients (pts) undergoing a solid organ (SOT) or allogeneic hematopoietic cell transplant (HCT) are at risk for developing Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+PTLD). There is a need for effective and well-tolerated therapies in… read more here.
Keywords: ebv ptld; transplant; tab cel;
Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124904
Abstract: Background: Patients (pts) undergoing solid organ (SOT) or allogeneic hematopoietic cell transplants (HCT) are at risk for developing Epstein-Barr (EBV) virus-driven post-transplant lymphoproliferative disorder (PTLD). Pts with EBV+PTLD not responding to rituximab ± chemotherapy after… read more here.
Keywords: ebv ptld; research; tabelecleucel; research funding ... See more keywords
Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.994552
Abstract: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. Predisposing factors include primary Epstein-Barr virus (EBV) infection, reactivation of EBV in recipient B cells, and decreased T cell immunity due to immunosuppression.… read more here.
Keywords: cell; expression; ptld; ebv ptld ... See more keywords